Form 4: Fairmount Funds Management Acquires Viridian Therapeutics Stock

Fairmount Funds Management LLC, along with its associated entities, has reported a significant acquisition of common stock in Viridian Therapeutics, Inc.

Summary

• Fairmount Funds Management LLC, acting on behalf of Fairmount Healthcare Fund II L.P., acquired 1,176,470 shares of common stock in Viridian Therapeutics, Inc. on May 11, 2026.
• The acquisition was made at a price of $17 per share.
• Following this transaction, Fairmount Healthcare Fund II L.P. beneficially owns 5,090,928 shares of Viridian Therapeutics, Inc. common stock.
• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over these securities.
• Tomas Kiselak, a Managing Member of Fairmount Funds Management LLC, also serves on the board of directors of Viridian Therapeutics, Inc., leading to the reporting persons being deemed directors by deputization.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as a substantial acquisition by a known investment fund often indicates confidence in the company's future prospects.

Positives

• Significant acquisition of common stock by a major investment fund, indicating confidence in Viridian Therapeutics, Inc.
• The acquisition of over 1.1 million shares at a defined price suggests a substantial investment.

Negatives

• The filing does not contain information that can be construed as negative.

Risks

• The filing does not explicitly mention any risks.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC disclaim beneficial ownership of securities held by Fund II, except to the extent of their pecuniary interest therein.
• Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC, leading to the reporting persons being deemed directors by deputization.

Industry Context

StockSavvy.ai notes that significant stock acquisitions by investment management firms in biotechnology companies like Viridian Therapeutics, Inc. often signal strong conviction in the company's pipeline or strategic direction, especially in a sector driven by innovation and clinical trial progress.

Stakeholder Impact

• Shareholders may view this acquisition positively, potentially leading to increased investor confidence and share price appreciation.
• The reporting persons, as significant owners and directors, have a vested interest in the company's performance.

Next Steps

• Continued monitoring of Fairmount Funds Management's beneficial ownership in Viridian Therapeutics, Inc.

Key Dates

Recommendation

The filing indicates a significant acquisition by an investment fund, which is generally a positive signal. However, as this is a Form 4 filing detailing ownership changes rather than financial results or strategic announcements, it warrants a 'hold' recommendation pending further information on the company's performance and strategy. It confirms existing or new significant investment rather than providing new operational insights.

Keywords

Viridian Therapeutics, Fairmount Funds Management, SEC Form 4, Stock Acquisition, Beneficial Ownership, Insider Trading, Healthcare, Biotechnology